Novo Nordisk's novel therapy could offer better outcomes for type 2 diabetes patients

5 March 2014

Danish insulin giant Novo Nordisk (NOV: N) has presented positive data at the Diabetes UK conference from its DUAL I and II (Dual Action of Liraglutide and Insulin Degludec in type 2 diabetes) studies.

The results show that the novel, once-daily type 2 diabetes treatment IDegLira results in a significantly greater reduction in blood sugar levels (HbA1c) versus basal insulin degludec (IDeg) Tresiba or glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide (Victoza) alone.

New data also demonstrate that IDegLira is associated with a mean weight loss of 2.7kg from baseline and a lower risk of hypoglycemia, compared to IDeg alone. IDegLira is a once-daily, fixed-ratio combination of IDeg and liraglutide under development for the treatment of type 2 diabetes in adults.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK